Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-2-11
pubmed:abstractText
Severe alcoholic hepatitis (AH) is associated with very high mortality. Tumor necrosis factor-alpha (TNF-alpha) contributes to the progression of AH and TNF-alpha antagonists like infliximab may help in ameliorating the severity and complications of AH. There is a scarcity of data regarding the safety and efficacy of infliximab monotherapy in the treatment of AH. We evaluated infliximab monotherapy in patients with severe AH.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0168-8278
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
584-91
pubmed:meshHeading
pubmed-meshheading:19155081-Adult, pubmed-meshheading:19155081-Anti-Inflammatory Agents, pubmed-meshheading:19155081-Antibodies, Monoclonal, pubmed-meshheading:19155081-Bacterial Infections, pubmed-meshheading:19155081-Bilirubin, pubmed-meshheading:19155081-Blood Proteins, pubmed-meshheading:19155081-Disease Progression, pubmed-meshheading:19155081-Hepatitis, Alcoholic, pubmed-meshheading:19155081-Humans, pubmed-meshheading:19155081-International Normalized Ratio, pubmed-meshheading:19155081-Leukocyte Count, pubmed-meshheading:19155081-Male, pubmed-meshheading:19155081-Middle Aged, pubmed-meshheading:19155081-Patient Selection, pubmed-meshheading:19155081-Serum Albumin, pubmed-meshheading:19155081-Survival Analysis, pubmed-meshheading:19155081-Survivors, pubmed-meshheading:19155081-Tumor Necrosis Factor-alpha, pubmed-meshheading:19155081-Young Adult
pubmed:year
2009
pubmed:articleTitle
Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial.
pubmed:affiliation
Department of Gastroenterology, G B Pant Hospital, University of Delhi, New Delhi, India.
pubmed:publicationType
Journal Article, Clinical Trial